Evidence map›Paper›PMID 37214795›Full record

ArticleResearch square2023

IFNα induces CCR5 in CD4

Hélène Le Buanec, Valérie Schiavon, Marine Merandet, Alexandre How-Kit, Hongshuo Song, David Bergerat, Céline Fombellida-Lopez, Armand Bensussan, Jean-David Bouaziz, Arsène Burny and 5 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 3 countries.

Hélène Le BuanecUniversité de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France.
Valérie SchiavonUniversité de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France.
Marine MerandetUniversité de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France.
Alexandre How-KitLaboratory for Genomics Foundation Jean Dausset-CEPH; Paris France.
Hongshuo SongInstitute of Human Virology, School of Medicine, University of Maryland; Baltimore MD, 21201, USA, Department of Medicine, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA.
David BergeratUniversité de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France.
Céline Fombellida-LopezLaboratory of Infectious Diseases, GIGA-I3, GIGA-Institute University of Liege; 4000 Liege, Belgium.
Armand BensussanUniversité de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France.ORCID 0000-0002-0409-2497
Jean-David BouazizUniversité de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France.
Arsène BurnyLaboratory of Molecular Biology, Gembloux Agrobiotech,University of Liège ;Belgium.
Gilles DarcisLaboratory of Infectious Diseases, GIGA-I3, GIGA-Institute University of Liege; 4000 Liege, Belgium.
Mohammad M SajadiInstitute of Human Virology, School of Medicine, University of Maryland; Baltimore MD, 21201, USA, Department of Medicine, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA.
Shyamasundaran KottililInstitute of Human Virology, School of Medicine, University of Maryland; Baltimore MD, 21201, USA, Department of Medicine, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA.
Daniel Zagury21CBIO ; Paris France.
Robert C GalloInstitute of Human Virology, School of Medicine, University of Maryland; Baltimore MD, 21201, USA, Department of Medicine, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA.
Université Paris Cité · FRUniversity of Maryland, Baltimore · USUniversity of Liège · BEInserm · FRBluebird Bio (France) · FRFondation Jean Dausset-CEPH · FR

Funding

Engineering of pan-neutralizing anti-HIV envelope antibodiesR01AI147870 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI SAJADI, MOHAMMAD MOHSENI · 2020 to 2024
$2.5M
BLRD VA I01 BX002358NIAID NIH HHS R01 AI147870
6 · The paper itself

Abstract

Like EC, we find that ART-treated patients control serum IFNα concentration and show few immune cell alterations enabling a healthy but fragile medical status. However, treatment interruption leads to elevated IFNα reflecting virus production indicating that like EC, ART does not achieve a virological cure. The immune system becomes overwhelmed by multiple immune cell abnormalities as found in untreated patients. These are chiefly mediated by elevated IFNα inducing signaling checkpoints abnormalities, including PD1, in cytotoxic immune cells. Importantly, during acute infection, elevated IFNα correlated with HIV load and we found that IFNα enhances CCR5, the HIV coreceptor in CD4

Identifiers

PMID37214795
PMCPMC10197818
OpenAlexW4376142500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.